Related Experiment Videos
Adriamycin impairs phagocytic function and induces morphologic alterations in human neutrophils
Cancer
|August 1, 1984
Summary
Adriamycin and daunomycin impair polymorphonuclear leukocyte (PMNL) function, hindering bacterial phagocytosis and killing. Other chemotherapy drugs did not affect PMNL function, suggesting specific toxicity from anthracyclines.
Area of Science:
- Immunology
- Pharmacology
- Cell Biology
Background:
- Polymorphonuclear leukocytes (PMNL) are crucial for innate immunity.
- Chemotherapeutic agents can have diverse effects on immune cells.
- Understanding drug-induced immune suppression is vital for patient care.
Purpose of the Study:
- To investigate the in vitro effects of various chemotherapy drugs on normal human PMNL function.
- To determine if anthracyclines, specifically Adriamycin (doxorubicin) and daunomycin, impact PMNL phagocytic and bactericidal capabilities.
Main Methods:
- Human PMNL were preincubated with methotrexate, 5-fluorouracil, vincristine, cisplatin, Adriamycin, and daunomycin.
- Phagocytic-bactericidal assays were performed to assess PMNL function.
- Oil Red-O particle uptake measured phagocytosis.
- Electron microscopy examined cellular morphology and ultrastructure.
Main Results:
- PMNL treated with Adriamycin and daunomycin exhibited defective phagocytosis and bacterial killing.
- Other tested chemotherapeutic agents did not impair PMNL function.
- Adriamycin significantly reduced particle ingestion in a dose-dependent manner.
- Electron microscopy revealed Adriamycin-induced PMNL morphological changes, including nuclear alterations and glycogen depletion.
Conclusions:
- Anthracyclines (Adriamycin, daunomycin) selectively impair PMNL phagocytic and bactericidal functions.
- Adriamycin's mechanism involves decreased particle ingestion and significant cellular damage.
- These findings suggest Adriamycin may contribute to decreased immune function in patients, beyond neutropenia.